AR120388A1 - VESTIBULAR SUPPORT CELL PROMOTERS AND THEIR USES - Google Patents

VESTIBULAR SUPPORT CELL PROMOTERS AND THEIR USES

Info

Publication number
AR120388A1
AR120388A1 ARP200103058A ARP200103058A AR120388A1 AR 120388 A1 AR120388 A1 AR 120388A1 AR P200103058 A ARP200103058 A AR P200103058A AR P200103058 A ARP200103058 A AR P200103058A AR 120388 A1 AR120388 A1 AR 120388A1
Authority
AR
Argentina
Prior art keywords
transgene
vestibular
support cell
vestibular support
cell promoters
Prior art date
Application number
ARP200103058A
Other languages
Spanish (es)
Inventor
Joseph Burns
Tyler Gibson
Gabriela Pregernig
Original Assignee
Decibel Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Decibel Therapeutics Inc filed Critical Decibel Therapeutics Inc
Publication of AR120388A1 publication Critical patent/AR120388A1/en

Links

Landscapes

  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La descripción proporciona polinucleótidos que contienen promotores de SLC6A14, así como también vectores que los contienen, que pueden usarse para promover la expresión de un transgén en células de apoyo vestibulares. Los polinucleótidos descritos en la presente pueden unirse operativamente a un transgén, tal como un transgén que codifica una proteína terapéutica, de forma tal que promueven la expresión de la célula de apoyo vestibular del transgén. Los polinucleótidos descritos en la presente pueden unirse operativamente a un transgén terapéutico y usarse para el tratamiento de sujetos que tienen o se encuentran en riesgo de desarrollar disfunción vestibular.The disclosure provides polynucleotides containing SLC6A14 promoters, as well as vectors containing them, that can be used to promote expression of a transgene in vestibular support cells. The polynucleotides described herein can be operably linked to a transgene, such as a transgene encoding a therapeutic protein, in such a way as to promote vestibular support cell expression of the transgene. The polynucleotides described herein can be operably linked to a therapeutic transgene and used for the treatment of subjects who have or are at risk of developing vestibular dysfunction.

ARP200103058A 2019-11-04 2020-11-04 VESTIBULAR SUPPORT CELL PROMOTERS AND THEIR USES AR120388A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962930520P 2019-11-04 2019-11-04

Publications (1)

Publication Number Publication Date
AR120388A1 true AR120388A1 (en) 2022-02-09

Family

ID=80782247

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200103058A AR120388A1 (en) 2019-11-04 2020-11-04 VESTIBULAR SUPPORT CELL PROMOTERS AND THEIR USES

Country Status (1)

Country Link
AR (1) AR120388A1 (en)

Similar Documents

Publication Publication Date Title
CO2019011450A2 (en) Tissue selective transgene expression
NI201800057A (en) ANTI-IL1RAP ANTIBODIES, BI-SPECIFIC ANTIGEN BINDING MOLECULES THAT BIND IL1RAP AND CD3, AND THEIR USES.
CO2019011995A2 (en) Processes for the production of tumor infiltrating lymphocytes and their uses in immunotherapy
NI201800027A (en) ANTI-BCMA ANTIBODIES, BISPECIFIC ANTIGENS BINDING MOLECULES THAT BIND BCMA AND CD3, AND USES OF THEM.
CL2017000515A1 (en) Cd123 linking agents and their use
GT201400166A (en) SYNTHETIC APELINE MIMETICS FOR THE CARDIAC INSUFFICIENCY TREATMENT
CO2017004728A2 (en) Compositions and methods to inhibit the expression of the hao1 gene (hydroxy acid oxidase 1 (glycolate oxidase)
CL2018001522A1 (en) Focalization of peptides to direct adeno-associated viruses (aavs)
CO2017000506A2 (en) Chimeric cll-1 antigen receptor
DOP2016000042A (en) ANTIBODIES AGAINST THE TYPE 1 (PAI-1) PLASMINOGEN ACTIVATOR INHIBITOR AND USES OF THE SAME
CL2015002941A1 (en) Therapeutic uses of empaglifozin
PE20191407A1 (en) USE OF GABOXADOL IN THE TREATMENT OF TINNITUS
BR112019004353A2 (en) Methods and Vectors for Treating CNS Disorders
CO2019009080A2 (en) Peptides and methods for the treatment of diabetes
CO2018002534A2 (en) Sedation methods and parenteral formulation for use during critical care treatment
CO6541617A2 (en) METHOD OF TREATMENT OF HEART FAILURE WITH STRESTRINE TYPE PEPTIDES
CO2020006443A2 (en) Methods and Compositions for Allogeneic Chimeric Antigen Receptor T Cell Dosing
CL2018002734A1 (en) Vitamin D treatment methods
CO2021010945A2 (en) Antibodies against alpha il-7r subunit and uses of these
MX2020004910A (en) Compositions and methods for the depletion of cd5+ cells.
AR104598A1 (en) METHODS FOR TREATMENT LINFOPROLIFERATIVE DISORDERS ASSOCIATED WITH THE EPSTEIN-BARR VIRUS THERAPY WITH T-CELLS
CL2018000742A1 (en) Use of trientine for the supply of copper to an ischemic tissue
ES2525009T3 (en) Glycoproteins that have lipid mobilization properties and therapeutic uses thereof
CO2019003865A2 (en) Therapeutic protein
MX2018002816A (en) Methods of treating multiple myeloma and plasma cell leukemia by t cell therapy.